Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Exchange Rate Effect (2016 - 2025)

China Pharma Holdings' Exchange Rate Effect history spans 16 years, with the latest figure at $3856.0 for Q4 2025.

  • For Q4 2025, Exchange Rate Effect rose 106.08% year-over-year to $3856.0; the TTM value through Dec 2025 reached $1250.0, up 101.91%, while the annual FY2025 figure was $1250.0, 101.91% up from the prior year.
  • Exchange Rate Effect reached $3856.0 in Q4 2025 per CPHI's latest filing, down from $42392.0 in the prior quarter.
  • In the past five years, Exchange Rate Effect ranged from a high of $50439.0 in Q4 2023 to a low of -$153626.0 in Q3 2022.
  • Average Exchange Rate Effect over 5 years is -$14411.6, with a median of -$2568.0 recorded in 2021.
  • The largest YoY upside for Exchange Rate Effect was 1283.72% in 2022 against a maximum downside of 3654.3% in 2022.
  • A 5-year view of Exchange Rate Effect shows it stood at -$14578.0 in 2021, then soared by 126.57% to $3874.0 in 2022, then soared by 1201.99% to $50439.0 in 2023, then plummeted by 225.7% to -$63400.0 in 2024, then surged by 106.08% to $3856.0 in 2025.
  • Per Business Quant, the three most recent readings for CPHI's Exchange Rate Effect are $3856.0 (Q4 2025), $42392.0 (Q3 2025), and -$39627.0 (Q2 2025).